Deciphering the Complexity of MEK Mutations in the Clinic.

Abstract

Significant advances in tumor sequencing have led to an explosion in our knowledge of the genetic complexity of cancer. For many cancers, the selection of a targetable alteration is not readily apparent, especially when confronted with mutational variants of unknown significance. The complex clinical landscape of <i>MEK</i> mutations illustrates the need for improved methods to identify those patients, independent of tumor histology, who would benefit from treatment with a MAP kinase pathway inhibitor. In this issue of <i>Cancer Research</i>, Hanrahan and colleagues adopt an <i>in silico</i> platform to attempt to distinguish benign <i>MEK</i> mutations from those that are functional and, therefore, most likely to be therapeutically actionable.<i>See related article by Hanrahan et al., p. 4233</i>.